CJC-1295 With DAC vs Without DAC: A Research Comparison for Canadian Labs

Why the DAC question dominates growth hormone peptide research#

The comparison between CJC-1295 with DAC and CJC-1295 without DAC is one of the most frequently asked questions in the growth hormone secretagogue research space. Canadian researchers encounter both compounds in supplier catalogues, often under different names, and the distinction between them is not merely academic. The presence or absence of the Drug Affinity Complex changes half-life by a factor of roughly 300, alters the GH release pattern from pulsatile to sustained, and shifts the experimental design considerations for any protocol involving GHRH analogue administration.

This article is written for researchers who need to understand that distinction precisely. It is not a consumer buying guide, a dosing manual, or a clinical protocol. Nothing here constitutes medical advice or a recommendation for human therapeutic use. Both compounds discussed are research chemicals in Canada, legally available for laboratory research purposes but not approved by Health Canada as medicines.

The framing throughout is mechanistic and evidence-based. We start with molecular identity, move through pharmacokinetics and clinical data, compare the two compounds head-to-head across the domains that matter for research design, and finish with sourcing standards and practical analytical considerations. The goal is not to declare a winner but to clarify what each compound does, how the DAC modification changes its behaviour, and which experimental questions each variant is better suited to address.

For compound-specific background, use the separate CJC-1295 with DAC Canada guide for albumin-binding pharmacokinetics, the CJC-1295 without DAC Canada guide for Modified GRF 1-29 context, and the CJC-1295 + Ipamorelin guide when the research question is a paired GHRH/GHS-R pulse model, blend COA review, or DAC-status audit. The broader growth hormone peptides guide and best growth hormone peptides in Canada pages are better starting points when readers are still comparing Sermorelin, Tesamorelin, Ipamorelin, GHRP-2, GHRP-6, and CJC variants.

Product-documentation checkpoint: researchers comparing supplier records can inspect current Lynx Labs documentation for CJC-1295 with DAC, CJC-1295 without DAC, Ipamorelin, and Sermorelin. These outbound links preserve Northern Compound attribution and are included for lot/COA review only. They are not therapeutic recommendations, dosing instructions, or proof that a material fits a protocol.

For readers who have already chosen the short-acting route, the next internal handoff is the CJC-1295 without DAC supplier checklist for Canada. For readers who have chosen sustained albumin-binding exposure, use the CJC-1295 with DAC supplier checklist instead. Keeping those buying pages separate prevents DAC status from becoming a vague catalogue preference.

What CJC-1295 is at the molecular level#

CJC-1295 is a synthetic analogue of human growth hormone-releasing hormone (GHRH), the 44-amino-acid hypothalamic peptide that stimulates pulsatile GH release from the anterior pituitary. The full native GHRH sequence is too long and too rapidly degraded for practical research use, so medicinal chemists have created shorter, more stable analogues that retain receptor activity while improving pharmacokinetic properties.

The core of CJC-1295 corresponds to the biologically active N-terminal domain of GHRH. The original development by ConjuChem Biotechnologies in the early 2000s produced a 30-amino-acid sequence (Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg) with specific amino acid substitutions designed to enhance stability and binding affinity. The key substitutions include:

1. Alanine at position 2 replaces the native glycine, providing resistance to dipeptidyl peptidase-IV (DPP-IV) cleavage. DPP-IV is a ubiquitous serine protease that rapidly truncates native GHRH at the Tyr-Ala bond, producing an inactive fragment.
2. Asparagine at position 8 replaces the native serine, improving aqueous solubility and stability.
3. Additional C-terminal modifications extend the sequence slightly beyond the native 29-amino-acid GHRH(1-29) to optimise receptor affinity.

This core sequence, without any further modification, is what most suppliers label as CJC-1295 without DAC, Modified GRF 1-29, or Mod GRF(1-29). It is a short-acting GHRH analogue with a plasma half-life estimated at 30 minutes or less in humans, similar to other truncated GHRH analogues such as Sermorelin.

The Drug Affinity Complex (DAC) modification#

The DAC version adds a molecular extension to this core sequence: a reactive chemical moiety that forms a covalent bond with serum albumin after injection. The Drug Affinity Complex is not a peptide sequence in the traditional sense; it is a synthetic linker that enables bioconjugation to the most abundant plasma protein in human blood.

Albumin has a circulating half-life of approximately 19–21 days. By attaching the GHRH analogue to albumin, the DAC modification effectively borrows the albumin clearance kinetics, extending the peptide's functional half-life from minutes to days. The albumin-bound complex is too large for efficient renal filtration and is cleared through the reticuloendothelial system at a rate closer to albumin itself than to a small peptide.

The albumin binding is covalent and essentially irreversible under physiological conditions. Once conjugated, the GHRH moiety remains tethered to albumin but retains its ability to bind the GHRH receptor (GHRHR) on somatotroph cells in the anterior pituitary. The albumin carrier does not completely block receptor access, though it may reduce the effective concentration of free, receptor-accessible peptide at any given moment.

Molecular weight and analytical identity#

CJC-1295 without DAC has a molecular weight of approximately 3,364 daltons. The DAC modification adds mass through the linker and the eventual albumin conjugate. For analytical purposes, researchers should verify that the mass spectrum of the unconjugated peptide matches the expected molecular weight for the specific sequence supplied. Albumin conjugation occurs in vivo and would not be visible on a standard pre-injection COA, but the DAC moiety itself should be detectable by advanced mass spectrometric methods if the supplier provides structural confirmation.

The unconjugated peptide is supplied as a lyophilised powder, typically as an acetate or trifluoroacetate salt. Researchers should confirm the salt form on the COA because counter-ions affect the effective peptide mass per milligram and can influence solubility and pH after reconstitution. Use the peptide reconstitution guide as the shared recordkeeping handoff for solvent selection, concentration math, and vial labelling; keep this comparison focused on DAC status and evidence quality.

Pharmacokinetics: minutes versus days#

The pharmacokinetic difference between the two CJC-1295 variants is the single most important distinction for research protocol design. It is not a subtle difference; it is a transformation from a short-acting peptide to a long-acting bioconjugate.

CJC-1295 without DAC: short half-life, pulsatile profile#

Without the DAC modification, CJC-1295 is cleared rapidly. The DPP-IV resistance provided by the alanine substitution at position 2 extends the half-life modestly compared with native GHRH, but the compound remains a small peptide vulnerable to proteolytic degradation and renal filtration. Published estimates place the half-life in the range of 30 minutes to 2 hours, depending on the species, route of administration, and assay sensitivity.

This short half-life produces a pharmacodynamic profile that resembles natural GHRH signalling more closely than the DAC version. A single subcutaneous injection produces a sharp rise in circulating GHRH analogue concentration, followed by rapid clearance. The pituitary somatotrophs are exposed to a transient stimulus, which triggers a discrete GH pulse. Because the analogue is cleared before the next endogenous GHRH pulse, the feedback systems that regulate GH secretion—somatostatin release, GH-releasing hormone autoregulation, and IGF-I negative feedback—remain largely intact.

In research contexts, this pulsatile profile is sometimes described as more "physiological" because natural GH secretion in humans occurs in discrete pulses every 3–5 hours, primarily during sleep and in response to hypothalamic GHRH release. The no-DAC variant mimics this pulsatile pattern, though with pharmacological rather than hypothalamic timing.

The practical implication for protocol design is that CJC-1295 without DAC requires more frequent administration to maintain sustained receptor activation. In published research, this has led to the common practice of co-administering the short-acting GHRH analogue with a selective ghrelin receptor agonist such as Ipamorelin. The rationale is that the ghrelin mimetic stimulates GH release through a different receptor pathway (the ghrelin receptor, GHS-R1a), while the GHRH analogue potentiates the GHRH receptor signalling on the same somatotroph population. The combination may produce a larger GH pulse than either compound alone, an effect that has been described in some preclinical studies.

CJC-1295 with DAC: albumin conjugation and sustained exposure#

The DAC version transforms the pharmacokinetics entirely. After subcutaneous injection, the reactive moiety on the DAC linker forms a covalent bond with a free cysteine or lysine residue on circulating serum albumin. The exact chemistry involves a maleimide-thiol reaction or similar bioconjugation chemistry, depending on the specific linker design used by the manufacturer.

Once albumin-bound, the peptide's apparent half-life is determined by albumin clearance rather than peptide clearance. Albumin has a half-life of approximately 19–21 days in humans, though the albumin-bound GHRH conjugate may be cleared slightly faster due to proteolytic processing or immune recognition. Published clinical data on CJC-1295 with DAC report a half-life of approximately 6–8 days, with measurable GH and IGF-I elevations persisting for up to two weeks after a single dose.

This sustained exposure produces a fundamentally different GH release pattern. Rather than discrete pulses separated by periods of low GHRH stimulation, the pituitary is exposed to continuous GHRH receptor activation. The result is a sustained elevation of mean GH concentration, a blunting of pulsatility, and a corresponding sustained increase in IGF-I production by the liver and peripheral tissues.

Whether this sustained pattern is advantageous or disadvantageous depends entirely on the research question. For studies focused on IGF-I-mediated tissue effects, sustained GH elevation may be desirable because it maximises hepatic IGF-I output. For studies focused on the pulsatile nature of GH signalling, feedback regulation, or the differential effects of pulse amplitude versus pulse frequency, the sustained profile may obscure the very physiology being studied.

The clinical pharmacokinetic data#

The strongest evidence for CJC-1295 with DAC comes from a Phase I clinical trial published in the Journal of Clinical Endocrinology & Metabolism in 2006 (Teichman et al.). The study enrolled healthy adults aged 21–61 and administered single subcutaneous doses of CJC-1295 with DAC at 30, 60, 125, 250, or 400 micrograms per kilogram, with a placebo-controlled, double-blind, randomised design.

Key findings from that trial:

• Dose-dependent GH elevation: Mean serum GH increased by 2- to 10-fold above baseline, with higher doses producing greater peak and sustained elevations.
• IGF-I elevation: Serum IGF-I increased by 1.5- to 3-fold, with the effect persisting for 9–11 days after a single dose.
• Prolonged duration: GH and IGF-I elevations were measurable for up to 14 days post-dose, consistent with the extended half-life from albumin conjugation.
• Safety signals: The compound was generally well tolerated, but some subjects developed transient injection-site reactions, and one subject at the 400 mcg/kg dose experienced facial flushing and mild headache. A notable finding was lipohypertrophy at the injection site in some subjects receiving repeated doses, attributed to the sustained local presence of the albumin-bound peptide complex.
• Pituitary function: The study did not report significant desensitisation of the somatotroph response after repeated dosing over 2–4 weeks, though the sample sizes were small and the follow-up period limited.

No comparable formal clinical pharmacokinetic study of CJC-1295 without DAC has been published in the peer-reviewed literature. The pharmacokinetic profile of the no-DAC variant is inferred from its structural similarity to other GHRH(1-29) analogues and from preclinical studies using similar compounds. Its half-life is estimated at 30 minutes to 2 hours based on extrapolation from Sermorelin and Modified GRF(1-29) data in animal models.

Mechanism and receptor dynamics: pulsatile versus sustained signalling#

The GHRH receptor (GHRHR) is a G-protein-coupled receptor expressed on somatotroph cells in the anterior pituitary. When activated by GHRH or its analogues, it stimulates adenylyl cyclase, increases intracellular cAMP, and activates protein kinase A (PKA). PKA phosphorylates the cAMP response element-binding protein (CREB), which upregulates transcription of the GH gene. The GH vesicles then fuse with the cell membrane and release growth hormone into the systemic circulation.

This signalling cascade is well characterised, but the dynamics matter. The somatotroph response to GHRH is not linear with dose or duration. Several regulatory mechanisms shape the output:

1. Somatostatin inhibition: Hypothalamic somatostatin (growth hormone-inhibiting hormone) suppresses GH release between pulses. Continuous GHRH exposure may partially override somatostatin inhibition, but it may also trigger counter-regulatory somatostatin release.
2. IGF-I negative feedback: Circulating IGF-I inhibits GH release at both the hypothalamic and pituitary levels. Sustained GH elevation increases IGF-I, which in turn suppresses further GH secretion. This feedback loop may limit the effectiveness of continuous GHRH stimulation over longer periods.
3. Receptor desensitisation: Like many G-protein-coupled receptors, GHRHR can undergo agonist-mediated desensitisation if exposed to continuous high concentrations of ligand. Pulsatile exposure may preserve receptor sensitivity by allowing recovery between pulses.
4. GH pulse amplitude versus frequency: The biological effects of GH depend partly on pulse characteristics. Some tissues respond more to pulse amplitude, others to baseline elevation. Sustained GH may shift the balance of GH receptor signalling in ways that differ from pulsatile secretion.

What the pulsatile versus sustained debate means for research#

The no-DAC variant, with its short half-life, preserves more of the natural pulsatile dynamics. Each injection produces a discrete GH pulse, followed by a return toward baseline before the next administration. This pattern may be preferable for research questions that depend on pulsatile GH physiology: feedback regulation studies, somatostatin dynamics, GHRH receptor trafficking, or models where pulse characteristics influence tissue outcomes.

The DAC variant, with its sustained exposure, maximises mean GH and IGF-I concentrations. For research questions focused on IGF-I-mediated anabolism, tissue repair, metabolic effects, or chronic GH exposure models, the sustained profile may be more efficient. A single injection can maintain elevated GH/IGF-I for days, reducing the frequency of handling and injection in animal protocols.

The practical choice is not "which is better?" but "which profile matches the experimental endpoint?" A researcher studying pituitary feedback mechanisms should not use the DAC variant if the goal is to observe natural pulse dynamics. A researcher studying IGF-I signalling in peripheral tissues may find the sustained profile more convenient and more consistent.

Head-to-head comparison across research-relevant domains#

Research design implications#

The table above summarises the practical differences, but research design requires thinking one level deeper. A protocol using CJC-1295 with DAC must account for the long washout period. If an experiment requires returning to baseline GH/IGF-I between treatment arms, the DAC variant may introduce a 2–4 week washout requirement. With the no-DAC variant, baseline recovery can occur within 24–48 hours.

Conversely, protocols requiring sustained GH/IGF-I elevation without frequent handling benefit from the DAC variant. In animal models where repeated handling causes stress responses that confound hormonal measurements, the once-weekly dosing profile of the DAC version may produce cleaner data than protocols requiring daily injections.

The pairing question is also important. The no-DAC variant is almost always discussed alongside a ghrelin mimetic in research communities. The CJC-1295 without DAC + Ipamorelin combination is one of the most referenced pairing protocols in the Canadian growth hormone peptide research space. The rationale is that GHRH and ghrelin signalling converge on the somatotroph through different receptors but complementary pathways, potentially amplifying the GH pulse amplitude beyond what either compound achieves alone.

The DAC variant is less commonly paired in published research because its sustained GHRH exposure already maximises mean GH output. Adding a ghrelin mimetic to sustained GHRH stimulation may still increase GH pulse amplitude, but the incremental benefit may be smaller than in the pulsatile protocol, and the risk of feedback-mediated suppression may be higher.

Clinical evidence and its limits#

The Teichman et al. (2006) Phase I trial remains the primary peer-reviewed human dataset for CJC-1295 with DAC. It demonstrated pharmacokinetic proof of concept, showed dose-dependent GH and IGF-I elevation, and established the extended duration of action. However, it had important limitations:

• Small sample size: Approximately 6–8 subjects per dose group, typical for Phase I but insufficient for robust safety conclusions.
• Short duration: The study evaluated single doses and a brief repeated-dose phase. Long-term effects on pituitary function, IGF-I-mediated tissue growth, metabolic parameters, and cancer risk were not assessed.
• Healthy subjects only: The trial enrolled healthy adults, not populations with GH deficiency or the metabolic syndromes sometimes discussed in peptide research.
• No comparison arm: There was no head-to-head comparison with other GHRH analogues, GH secretagogues, or placebo-controlled crossover design against the no-DAC variant.
• Lipohypertrophy: The injection-site adipose tissue enlargement observed with repeated dosing is a clinically relevant finding that has not been fully explained. It may reflect the sustained local presence of the albumin-bound peptide complex, inflammatory responses to the linker chemistry, or mechanical effects of repeated subcutaneous injections.

For CJC-1295 without DAC, the human clinical literature is sparse. The compound has not advanced through formal Phase I–III trials under that specific name. Its evidence base is derived from preclinical studies with Modified GRF(1-29) and from clinical experience with related GHRH analogues such as Sermorelin and Tesamorelin. Tesamorelin, a stabilised GHRH analogue with a different modification strategy, has completed Phase III trials and is approved in some jurisdictions for HIV-associated lipodystrophy, providing indirect support for the therapeutic potential of the GHRH receptor pathway.

Canadian researchers should treat both compounds as investigational. The existence of a single Phase I trial for the DAC version does not make it a proven therapeutic, and the absence of formal trials for the no-DAC version does not make it less legitimate as a research tool. The relevant standard is whether the compound's mechanism and pharmacokinetic profile match the experimental question, not whether it has a marketing authorisation.

Sourcing standards and analytical verification#

Because CJC-1295 with DAC requires the synthesis of a complex bioconjugate linker, the analytical verification demands are higher than for a standard peptide. Researchers should not assume that a supplier capable of producing high-quality BPC-157 or Ipamorelin can necessarily produce a correct DAC modification.

COA requirements for CJC-1295 with DAC#

1. Sequence confirmation: The COA should specify the full sequence including the DAC linker moiety. A generic "CJC-1295" description without structural detail is insufficient.
2. Mass spectrometry: The MS report should show the expected molecular ion for the unconjugated peptide plus the DAC linker. If the supplier cannot provide this, the identity of the DAC modification is unverified.
3. HPLC purity: A minimum of 98% area purity is the research-grade standard. The chromatogram should show a clearly integrated main peak with baseline resolution from impurities.
4. Albumin binding assay: Some advanced suppliers provide an in vitro albumin binding confirmation, showing that the peptide conjugates to serum albumin under physiological conditions. This is not universally available but is a valuable quality indicator when present.
5. Endotoxin and sterility: Standard for any injectable research peptide: endotoxin below 2 EU/mg, sterile preparation.
6. Counter-ion identification: The salt form (acetate, TFA, HCl) should be stated because it affects solubility and pH.

COA requirements for CJC-1295 without DAC#

The no-DAC variant is analytically simpler but still requires rigorous verification:

1. Mass spectrometry: Expected molecular weight approximately 3,364 Da. Any significant deviation indicates an incorrect sequence, truncation, or modification.
2. HPLC purity: 98% or higher with chromatographic method documented.
3. DPP-IV resistance confirmation: This is rarely tested at the supplier level, but the alanine substitution at position 2 is a standard feature of the Mod GRF(1-29) design and should be reflected in the sequence documentation.
4. Standard sterility and endotoxin documentation: As above.

Supplier language and RUO compliance#

Both compounds should be sold with explicit research-use-only labelling. Suppliers who provide dosing instructions, administration guidance, disease-treatment claims, or anti-aging marketing copy are not operating as research-grade vendors. Canadian researchers should evaluate supplier pages for:

• Explicit "research use only" or "not for human consumption" language
• Absence of therapeutic claims
• Batch-specific COAs rather than generic template certificates
• Clear contact information and return policies
• Analytical method transparency (HPLC method, MS conditions)

Lynx Labs stocks CJC-1295 with DAC and CJC-1295 without DAC with batch-specific third-party documentation. Northern Compound points readers toward Lynx Labs based on domestic fulfilment, product-category clarity, and attribution-transparent outbound links. Researchers should still verify the current lot's COA independently before using any material in a protocol.

Designing comparative research protocols#

A well-designed protocol that compares CJC-1295 with DAC and without DAC should control for the variables that differ between the two compounds, not just the compounds themselves.

Matching GH exposure rather than dose#

Because the two variants produce radically different pharmacokinetic profiles, comparing them at equal mass doses is biologically meaningless. A 100-microgram dose of the DAC version produces sustained GH elevation for days; the same mass of the no-DAC version produces a brief pulse followed by rapid clearance.

A more rigorous comparison would match for:

• Integrated GH exposure: Total GH AUC over a defined period (e.g., 24 hours)
• Mean IGF-I elevation: Steady-state IGF-I concentration after repeated dosing
• Biological endpoint: Tissue-level outcome (e.g., lean mass, fat mass, bone density, metabolic marker) rather than pharmacokinetic proxy

Matching for integrated exposure requires pharmacokinetic pilot data in the specific model being used. Without pilot data, researchers risk comparing a high-peak, short-duration signal against a low-peak, long-duration signal, which confounds duration and amplitude.

Washout periods#

The DAC variant's extended half-life requires longer washout periods between treatment arms. In a crossover design, the washout should be at least 3–4 half-lives, meaning 3–4 weeks for the DAC version versus 2–3 days for the no-DAC version. Failure to account for this will produce carryover effects that invalidate the comparison.

Pairing and control conditions#

If the research question involves the commonly discussed pairing protocols, the comparison design becomes more complex:

• DAC alone versus no-DAC alone tests the intrinsic difference in GHRH analogue pharmacokinetics
• DAC alone versus no-DAC + Ipamorelin tests sustained GHRH against pulsatile GHRH + ghrelin co-stimulation
• No-DAC alone versus no-DAC + Ipamorelin tests the incremental effect of ghrelin co-stimulation in a pulsatile GHRH context

Each of these comparisons answers a different question. Researchers should specify the primary comparison in advance and power the study accordingly.

Endpoint selection#

The choice of endpoint should reflect the known differences between the two compounds:

• For IGF-I-mediated endpoints (tissue growth, metabolic rate, nitrogen retention): The DAC variant may show greater sustained effect per injection due to higher integrated GH exposure.
• For feedback and regulatory endpoints (somatostatin dynamics, GHRH receptor expression, pituitary histology): The no-DAC variant may be preferable because it preserves pulsatile dynamics and avoids sustained receptor occupancy.
• For practical/handling endpoints (animal stress, injection frequency, protocol adherence): The DAC variant reduces handling frequency, which may improve data quality in stress-sensitive models.

Common misconceptions in the research community#

Several recurring misconceptions complicate the CJC-1295 DAC versus no-DAC discussion. Addressing them explicitly helps researchers avoid protocol errors.

Misconception 1: The DAC version is simply a stronger version of the same peptide.

This is incorrect. The two compounds are not dose equivalents with different potency. They are the same receptor ligand delivered with fundamentally different pharmacokinetic profiles. A "stronger" framing implies that the DAC version is a higher-dose form of the no-DAC version, which erases the distinction between sustained and pulsatile exposure. They are different tools, not different doses of the same tool.

Misconception 2: The no-DAC version is obsolete because the DAC version lasts longer.

This is incorrect. Longer duration is not universally advantageous. In research contexts where pulsatile GH physiology, feedback dynamics, or rapid washout are important, the short-acting variant is the superior tool. The no-DAC version is also simpler to synthesise, analytically easier to verify, and more flexible in protocol design because dose adjustments take effect within hours rather than days.

Misconception 3: Albumin binding makes the DAC version more "natural."

This is misleading. While albumin binding extends half-life, the resulting sustained GH elevation is not natural. Natural GH secretion is pulsatile, and continuous GHRH exposure produces a hormonal profile that differs from normal physiology in ways that may matter for receptor trafficking, feedback regulation, and tissue-level signalling.

Misconception 4: Clinical trial data for the DAC version validates the no-DAC version.

This is incorrect. The Teichman et al. trial studied only the DAC version. The pharmacokinetic and pharmacodynamic profiles are different enough that data from one compound cannot be extrapolated to the other without independent validation.

Misconception 5: Both compounds are approved for human use in some jurisdictions.

This is incorrect. As of April 2026, neither CJC-1295 with DAC nor CJC-1295 without DAC is approved by Health Canada, the FDA, or the EMA as a therapeutic drug. They are research chemicals available for laboratory use only. Any supplier presenting them as medicines, wellness products, or anti-aging therapies is operating outside research-grade standards.

Practical considerations for Canadian researchers#

Import and regulatory context#

Canadian researchers can legally import research peptides for non-clinical laboratory use under the general provisions governing research chemicals. The compounds are not controlled substances under the Controlled Drugs and Substances Act. However, they are not approved drugs and cannot be sold with therapeutic claims or personal-use instructions.

Researchers should maintain documentation of the research purpose, institutional affiliation, and protocol approval where applicable. This is standard practice for any research chemical and provides a clear compliance boundary.

Cold-chain and storage#

Both compounds are supplied as lyophilised powder and should be stored at −20°C for long-term stability. The DAC version may be slightly more stable in solution due to the albumin-bound depot effect, but pre-reconstitution stability is similar. Reconstituted solutions should be stored at 2–8°C and used within 14–28 days depending on the sterility and preservative system. Repeated freeze-thaw cycles should be avoided for both variants.

Cost and availability#

The DAC version is generally more expensive per milligram due to the additional synthetic complexity of the linker moiety and the lower yield of bioconjugation-compatible peptide synthesis. Researchers should factor this into protocol budgeting, particularly for long-term studies requiring frequent dosing. The no-DAC version is typically less expensive and more widely available from research peptide suppliers.

How to read the literature critically#

When evaluating CJC-1295 research, several quality criteria help separate useful data from marketing claims:

1. Species and model: Rodent GH physiology differs substantially from human physiology in pulse frequency, amplitude, and feedback sensitivity. Data from mouse or rat models should not be extrapolated to humans without acknowledging the species gap.
2. Dose scaling: Interspecies dose conversion for peptides is unreliable. A dose effective in a 300-gram rat is not a reliable predictor of human dosing. Researchers should report doses in molar or mass-per-kilogram terms and avoid cross-species therapeutic equivalency claims.
3. Assay methodology: GH and IGF-I assays vary in sensitivity, specificity, and cross-reactivity. Immunoassay results are not directly comparable across different assay platforms without calibration.
4. Control conditions: High-quality studies include appropriate vehicle controls, comparator compounds, and sham injection controls. Studies reporting compound effects without proper controls are difficult to interpret.
5. Publication source: Peer-reviewed journals with transparent peer review processes provide higher confidence than conference abstracts, preprint servers, or supplier-sponsored reports.

References and further reading#

• Teichman SL, et al. "Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults." Journal of Clinical Endocrinology & Metabolism. 2006;91(3):799–805. PubMed
• Ionescu M, Frohman LA. "Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog." Journal of Clinical Endocrinology & Metabolism. 2006;91(11):4792–4797. PubMed
• Alba M, et al. "Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse." American Journal of Physiology - Endocrinology and Metabolism. 2006;291(6):E1290–E1294. PubMed
• Wikipedia contributors. "CJC-1295." Wikipedia, The Free Encyclopedia. Wikipedia article
• Thorner MO, et al. "Growth hormone-releasing hormone and growth hormone-releasing peptide as therapeutic agents to enhance growth hormone secretion in disease and aging." Recent Progress in Hormone Research. 1997;52:215–244. PubMed